Company Overview of ARCA biopharma, Inc.
ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3...
11080 CirclePoint Road
Westminster, CO 80020
Key Executives for ARCA biopharma, Inc.
Co-Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $296.7K
Chief Operating Officer
Total Annual Compensation: $294.2K
Senior Vice President, General Counsel and Secretary
Total Annual Compensation: $290.0K
Compensation as of Fiscal Year 2015.
ARCA biopharma, Inc. Key Developments
Anders Hove Joins ARCA Biopharma Board of Directors
Feb 21 17
ARCA biopharma, Inc. announced that Anders Hove, M.D., has joined its board of directors. Dr. Hove has more than 20 years of experience investing in and helping build biopharmaceutical companies. He has served on the boards of directors of numerous private and public companies, currently serving on the boards of two private biopharmaceutical companies.
ARCA biopharma, Inc. Announces Patient Randomized into the Genetic-AF Phase 2B/3 Clinical Trial
Jan 18 17
ARCA biopharma, Inc. announced that the 150th patient has been randomized into GENETIC-AF, a seamless Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF). GENETIC-AF is a seamless Phase 2B/3 adaptive design superiority trial evaluating the effectiveness of Gencaro for the prevention of recurrent atrial fibrillation or flutter (AF/AFL) in heart failure patients with reduced left ventricular ejection fraction (HFrEF). The DSMB will perform a pre-specified interim analysis of unblinded efficacy data when at least 150 patients have evaluable data. A randomized patient has evaluable data either when they experience their first composite endpoint event, AF/AFL or all-cause mortality, or after completion of the 24-week primary endpoint follow-up period. The analysis will be conducted for detection of evidence of safety and superior efficacy of Gencaro versus the active comparator, metoprolol succinate (TOPROL-XL).
ARCA biopharma Mulls Acquisitions
Jan 11 17
ARCA biopharma, Inc. (NasdaqCM:ABIO) is seeking acquisitions. ARCA announced an equity offering with an offering price of up to $7.3 million. It may also use a portion of the net proceeds to invest in or acquire businesses or technologies that we believe are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries